8,304 Results

CHMP negative against Sutent for the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.- Pfizer.

 Added 1 day ago

Pfizer Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...

CHMP positive opinion for Kineret to treat Still’s disease.- SOBI

 Added 1 day ago

Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still’s disease. Swedish Orphan Biovitrum AB (publ) (Sobi)...

Results of PIONEER study of oral semaglutide for type 2 diabetes,.- Novo Nordisk.

 Added 1 day ago

Novo Nordisk announced the headline results from PIONEER 1, the first phase IIIa trial with oral semaglutide for treatment of...

FDA accepts BLA for SHP 643 to treat hereditary angioedema

 Added 1 day ago

Shire plc announced the FDA accepted the Biologics License Application (BLA) and granted priority review for lanadelumab (SHP 643). Lanadelumab...

CHMP recommends Lynparza as maintenance therapy for ovarian cancer regardless of BRCA status. AstraZeneca + Merck Inc.

 Added 1 day ago

AstraZeneca and Merck & Co., Inc., announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Update on CHMP review of andexanet alfa for reversal of anticoagulation. - Portola Pharma.

 Added 1 day ago

Portola Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Update on forthcoming CHMP decision for betrixaban as a treatment for venous thromboembolism.- Portola Pharma

 Added 1 day ago

Portola Pharmaceuticals Inc.'s Factor Xa inhibitor betrixaban's future in the EU is looking uncertain after the EMA's CHMP issued a...

Update on EMA marketing review of rucaparib for advanced ovarian cancer with BRCA mutation- Clovis Oncology.

 Added 1 day ago

Clovis Oncology, Inc. announced an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets...

NEJM publishes clinical details of larotrectinib, a treatment for TRK Fusion cancers.-Loxo Oncology + Bayer.

 Added 2 days ago

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, and...

CLAIM study of Ultibro Breezhaler shows reduction of lung hyperinflation in COPD patients.-Novartis.

 Added 2 days ago

Novartis announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler...

Load more